Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Recent Research on Diabetes Mellitus, Non-Hodgkin Lymphoma Link

October 18, 2019
By Leanne Marcello, MS
News
Article

After conflicting opinions over the years, a study published in the journal Hematology explores the association between diabetes mellitus non-hodgkin lymphoma.

After conflicting opinions over the years, a study published in the journal Hematology found a definitive association between diabetes mellitus (DM) and a greater risk of non-hodgkin lymphoma (NHL).

Diabetes mellitus is a leading public health threat worldwide, and one that affects 3–4% of adults globally. DM contributes to as many as 1.3 million deaths around the globe each year. Scientists predict that DM will be among the five leading disease burdens worldwide by the year 2030. It has previously been established in myriad research that diabetes mellitus is a significant risk factor in the development or prognosis of many disease processes. A diagnosis of DM puts people at risk for cardiovascular disease, dementia, kidney failure, liver ailments, and a number of solid tumors, including those of the pancreas, colon, liver, breast, ovaries, endometrium, lung, and prostate. In addition, prior meta-analyses suggest that DM patients might be at greater risk for one or more hematologic malignancies as well.

Non-Hodgkin lymphoma is a fairly prevalent blood cancer that arises from lymphocytes. It is found more often in developed countries and represents 4.3% of all new cancer diagnoses in the United States. In recent years, it has ranked as high as 7th in males and 6th in females as leading cancer. NHL has been on the rise in Western countries in the new century, particularly in the white, male, and elderly populations. Researchers have labored to identify the pathophysiology of NHL, but they have yet to narrow down its causes.

Although a recent study in Japan, showed that males with DM were at greater risk of developing NHL, while females were not, the relationship between DM and lifetime risk of NHL is something researchers have not yet come to an agreement on either.

In this meta-analysis of cohort studies, the authors investigated the association between the two.

The authors conducted a systematic search of PubMed, the Cochrane Library, and EmBase to identify eligible studies that began no earlier than September of 2018, which led them to 13 cohort studies with a combined total of 9024761 participants. THe researchers discovered that DM was repeatedly associated with an increased risk of NHL (RR = 1.15, 95%CI: 1.02, 1.30, P = .03). Conducting analyses of subgroups, the authors found that DM was most frequently associated with patients under the age of 60 years (RR = 1.65, 95%CI: 1.31, 2.09, P < .0001), follow-up duration within 8 years (RR = 1.23, 95%CI: 1.02, 1.48, P = .03), and studies adjusted for body mass index (RR = 1.35, 95%CI: 1.01, 1.79, P = .04). The investigators also determined that men with DM were more likely to develop NHL than women were (RR = 1.31, 95%CI: 1.04, 1.65, P = .02).
The study authors concluded that patients with DM patients are at substantially greater risk of developing NHL in comparison with nondiabetics, and that male patients with diabetes have the greater likelihood in comparison with females. Further studies should be conducted to rule out miscellaneous factors that may have skewed results.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Symposiums and regional meetings may expand knowledge of how to adopt novel CAR T-cell therapies and bispecific antibodies, said Suman Kambhampati, MD.
Related Content
Advertisement

Data from the BRUIN-CLL-321 trial led to the FDA granting traditional approval to pirtobrutinib in CLL/SLL indications.

FDA Gives Traditional Approval to Pirtobrutinib in CLL/SLL

Ariana Pelosci
December 3rd 2025
Article

Data from the BRUIN-CLL-321 trial led to the FDA granting traditional approval to pirtobrutinib in CLL/SLL indications.


Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.


Tisa-Cel Maintains Efficacy at 5-Year Analysis in R/R LBCL

Tisa-Cel Maintains Efficacy at 5-Year Analysis in R/R LBCL

Ariana Pelosci
November 26th 2025
Article

ORR, DOR, PFS, and OS showed continued improvement for patients with relapsed/refractory LBCL receiving tisagenlecleucel.


A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.


Results from the TRANSCEND NHL 001 trial showed that liso-cel achieved an ORR of 82.7% in patients with previously treated mantle cell lymphoma.

EU Approves Liso-Cel in R/R MCL With ≥ 2 Prior Lines of Systemic Therapy

Tim Cortese
November 25th 2025
Article

Results from the TRANSCEND NHL 001 trial showed that liso-cel achieved an ORR of 82.7% in patients with previously treated mantle cell lymphoma.


Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence

Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence

American Society for Transplantation and Cellular Therapy
November 24th 2025
Article

Researchers have observed that HSC–derived innate lymphoid cells prevent GVHD by inducing interleukin 9 driven T-cell senescence.

Related Content
Advertisement

Data from the BRUIN-CLL-321 trial led to the FDA granting traditional approval to pirtobrutinib in CLL/SLL indications.

FDA Gives Traditional Approval to Pirtobrutinib in CLL/SLL

Ariana Pelosci
December 3rd 2025
Article

Data from the BRUIN-CLL-321 trial led to the FDA granting traditional approval to pirtobrutinib in CLL/SLL indications.


Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.


Tisa-Cel Maintains Efficacy at 5-Year Analysis in R/R LBCL

Tisa-Cel Maintains Efficacy at 5-Year Analysis in R/R LBCL

Ariana Pelosci
November 26th 2025
Article

ORR, DOR, PFS, and OS showed continued improvement for patients with relapsed/refractory LBCL receiving tisagenlecleucel.


A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.


Results from the TRANSCEND NHL 001 trial showed that liso-cel achieved an ORR of 82.7% in patients with previously treated mantle cell lymphoma.

EU Approves Liso-Cel in R/R MCL With ≥ 2 Prior Lines of Systemic Therapy

Tim Cortese
November 25th 2025
Article

Results from the TRANSCEND NHL 001 trial showed that liso-cel achieved an ORR of 82.7% in patients with previously treated mantle cell lymphoma.


Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence

Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence

American Society for Transplantation and Cellular Therapy
November 24th 2025
Article

Researchers have observed that HSC–derived innate lymphoid cells prevent GVHD by inducing interleukin 9 driven T-cell senescence.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.